MYD88 and Alzheimer disease: Knockout studies suggest differential effects of TLRs on AD progression; deletion of CD14, a co-receptor for TLR2/4, reduces plaque burden in a murine AD model [62], but deletion of MyD88 enhances memory deficits [63].